Related Experiment Videos
Primary central nervous system lymphomas in immunocompetent patients
T Alécio-Mattei1, J Alécio-Mattei, P H Aguiar
1Pinheiros Neurosurgery Clinic, São Paulo, Brazil.
Neurocirugia (Asturias, Spain)
|March 28, 2006
Summary
Primary central nervous system lymphoma (PCNSL) in immunocompetent patients is rare. Complete surgical resection with radiotherapy shows good results, with chemotherapy recommended only in select cases.
Area of Science:
- Neuro-oncology
- Immunology
- Pathology
Background:
- Primary central nervous system lymphoma (PCNSL) is a rare malignancy, typically affecting immunocompromised individuals.
- This study focuses on PCNSL occurring in immunocompetent patients, a less common presentation.
Purpose of the Study:
- To present a case series of PCNSL in immunocompetent patients.
- To review current literature on PCNSL diagnosis and management in this population.
- To highlight recent advances and controversies in the field.
Main Methods:
- Analysis of nine immunocompetent PCNSL patients, including demographics, symptoms, and treatment.
- Comparison of clinical data with existing literature.
- Review of diagnostic and therapeutic strategies.
Main Results:
- The study included patients aged 44-68 years, with 62.5% females.
- Common symptoms included hemiparesis (75%), headache (37.5%), seizures (25%), and ataxia (25%).
- Diffuse B-cell lymphoma was the most frequent histological type, with surgical resection and radiotherapy demonstrating positive outcomes.
Conclusions:
- Complete surgical resection followed by radiotherapy is an effective treatment for PCNSL in immunocompetent patients.
- Chemotherapy is considered a secondary treatment option, reserved for specific cases.
- Findings suggest a potential divergence from established treatment protocols in the literature.